---
title: "Dr Agarwals Health Care Ltd (AGARWALEYE) — Share Price, Financials & Analysis"
symbol: "AGARWALEYE"
company: "Dr Agarwals Health Care Ltd"
canonical: "https://tapetide.com/stocks/AGARWALEYE"
isin: "INE943P01029"
nse_symbol: "AGARWALEYE"
bse_code: "544350"
sector: "Healthcare Services"
industry: "Hospitals"
market_cap_cr: 15820.62
generated_at: "2026-09-13T18:50:24.938Z"
---

# Dr Agarwals Health Care Ltd (AGARWALEYE)

Canonical page: https://tapetide.com/stocks/AGARWALEYE

## Company

- **NSE Symbol:** AGARWALEYE
- **BSE Code:** 544350
- **ISIN:** INE943P01029
- **Sector:** Healthcare Services
- **Industry:** Hospitals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2025-02-04
- **CEO:** Dr. Adil Agarwal M.B.B.S, M.S, MBA
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** dragarwals.co.in

## About

Incorporated in 2010,[1]Dr. Agarwal’s Health Care offers a wide array of eye care services, which include cataract and refractive surgeries, consultations, diagnoses, and non-surgical treatments. Additionally, they provide optical products, contact lenses, accessories, and pharmaceutical items related to eye care.  [2]

## Latest Price

- **Price:** ₹508.4
- **Change:** +0.05 (+0.01%)
- **Open:** ₹503
- **Day High:** ₹511.85
- **Day Low:** ₹493.25
- **Previous Close:** ₹508.35
- **Volume:** 183331
- **As Of:** 2026-09-11T10:27:39+00:00

## Key Fundamentals

Observed at 2026-09-11T04:54:15.527802Z.

- **Market Cap:** ₹15820.62 Cr
- **Classification:** Smallcap
- **P/E (reported):** 86.5
- **P/E (TTM):** 108.4
- **EPS (TTM):** ₹4.69
- **Book Value:** ₹63.89
- **Price to Book:** 7.9
- **Dividend Yield:** 0%
- **ROE:** 5.73%
- **ROCE:** 8.41%
- **Debt to Equity:** 0.53
- **Revenue (yearly):** ₹2080.08 Cr
- **Net Income:** ₹167.69 Cr
- **EBITDA:** ₹569.57 Cr
- **52-Week High:** ₹568
- **52-Week Low:** ₹401
- **RSI (14):** 50.79

## Tapetide Score

- **Score:** 39 / 100
- **Score date:** 2026-09-04
- **Archetype:** Expensive and Under Pressure
- **What it means:** The multiple is demanding and the trend has turned against it, without the financial strength that would justify paying up. What matters is whether the de-rating stops at the multiple or starts showing up in the numbers.
- **Pillar profile:** Quality: Average · Valuation: Expensive · Momentum: Falling
- **Percentile:** 12 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 19.18 | 9% |
| growth | 65.87 | 9% |
| momentum | 46.74 | 12% |
| ownership | 45.63 | 24% |
| quality | 50.98 | 22% |
| valuation | 18.9 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Weaknesses

- Stock is trading at 7.95 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 6.11% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 4.14% | 54.58% | 263.38% |
| ebitda margin growth | 0.8% | -6.3% | -9.31% | -4.29% |
| net income growth | 10% | 52.03% | 13% | 34% |
| revenue growth | 7.34% | 18.39% | 27% | 35% |
| roce | -0.19% | -16.24% | -17.63% | 8.01% |
| roe | 10.13% | -16.84% | 9.43% | -119.5% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 333 | 349 | 403 | 417 | 431 | 460 | 487 | 499 | 530 | 564 | 614 |
| Expenses | 244 | 241 | 300 | 310 | 316 | 329 | 360 | 363 | 386 | 403 | 444 |
| Operating Profit | 89 | 108 | 104 | 107 | 115 | 131 | 128 | 136 | 144 | 161 | 170 |
| OPM % | 27 | 31 | 26 | 26 | 27 | 28 | 26 | 27 | 27 | 29 | 28 |
| Other Income | 12 | 20 | 6 | 12 | 13 | 13 | 13 | 8 | 11 | 14 | 6 |
| Interest | 22 | 27 | 27 | 28 | 28 | 25 | 25 | 23 | 21 | 22 | 23 |
| Depreciation | 43 | 47 | 56 | 57 | 58 | 60 | 63 | 68 | 69 | 77 | 78 |
| Profit before tax | 36 | 54 | 27 | 33 | 41 | 59 | 54 | 54 | 65 | 77 | 75 |
| Tax % | 37 | 24 | 33 | 36 | 31 | 27 | 29 | 32 | 33 | 35 | 27 |
| Net Profit | 23 | 41 | 18 | 21 | 28 | 43 | 38 | 36 | 44 | 50 | 55 |
| EPS in Rs | — | — | — | — | 0.72 | 1.03 | 0.95 | 0.94 | 1.07 | 1.25 | 1.43 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 531 | 471 | 696 | 1018 | 1332 | 1711 | 2080 | 2207 |
| Expenses | 407 | 387 | 510 | 743 | 965 | 1248 | 1511 | 1595 |
| Operating Profit | 124 | 85 | 186 | 275 | 367 | 463 | 570 | 612 |
| OPM % | 23 | 18 | 27 | 27 | 28 | 27 | 27 | 28 |
| Other Income | 13 | 6 | 17 | 14 | 44 | 43 | 46 | 39 |
| Interest | 54 | 44 | 49 | 76 | 101 | 115 | 90 | 89 |
| Depreciation | 93 | 95 | 98 | 128 | 170 | 231 | 276 | 292 |
| Profit before tax | -11 | -48 | 57 | 84 | 141 | 160 | 249 | 270 |
| Tax % | 82 | 21 | 24 | -24 | 32 | 31 | 32 | — |
| Net Profit | -21 | -59 | 43 | 103 | 95 | 110 | 168 | 185 |
| EPS in Rs | — | — | — | — | — | 2.64 | 4.2 | 4.69 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 7 | 7 | 7 | 8 | 9 | 32 | 32 |
| Reserves | 242 | 177 | 206 | 622 | 1330 | 1835 | 1994 |
| Borrowings | 162 | 185 | 633 | 857 | 966 | 961 | 1066 |
| Other Liabilities | 339 | 417 | 179 | 336 | 445 | 837 | 850 |
| Total Liabilities | 751 | 787 | 1025 | 1823 | 2751 | 3665 | 3942 |
| Fixed Assets | 551 | 575 | 701 | 1293 | 1746 | 2523 | 2879 |
| CWIP | 8 | 11 | 28 | 99 | 118 | 153 | 234 |
| Investments | 1 | 0 | 0 | 34 | 471 | 264 | 152 |
| Other Assets | 192 | 201 | 295 | 397 | 416 | 724 | 676 |
| Total Assets | 751 | 787 | 1025 | 1823 | 2751 | 3665 | 3942 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 103 | 99 | 164 | 233 | 346 | 360 | 519 |
| Cash from Investing Activity | -85 | -46 | -155 | -509 | -914 | -750 | -308 |
| Cash from Financing Activity | -73 | -37 | 35 | 303 | 553 | 382 | -220 |
| Net Cash Flow | -56 | 17 | 44 | 27 | -15 | -8 | -10 |
| Free Cash Flow | -98 | 66 | 95 | 76 | 118 | 40 | 59 |
| CFO/OP | 97 | 126 | 97 | 98 | 103 | 86 | 101 |

### Ratios

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 36 | 36 | 30 | 27 | 27 | 26 | 28 |
| Inventory Days | 178 | 169 | 144 | 116 | 138 | 181 | 178 |
| Days Payable | 340 | 452 | 389 | 326 | 355 | 345 | 283 |
| Cash Conversion Cycle | -126 | -247 | -215 | -183 | -190 | -138 | -76 |
| Working Capital Days | -31 | -47 | -50 | -62 | -65 | -44 | -3 |
| ROCE % | — | -1 | 17 | 13 | 11 | 10 | 11 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 37.83% | 32.45% | 32.42% | 32.42% | 32.39% | 32.36% | 32.34% |
| FIIs | 0% | 60.62% | 59.26% | 58.13% | 58.06% | 57.94% | 57.96% |
| DIIs | 0% | 5.21% | 6.44% | 7.92% | 7.78% | 7.83% | 7.72% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 0% | 1.61% | 1.74% | 1.41% | 1.62% | 1.68% | 1.81% |
| Others | 62.17% | 0.11% | 0.14% | 0.11% | 0.15% | 0.19% | 0.17% |
| No. of Shareholders | 29 | 68696 | 63021 | 48168 | 46554 | 43538 | 42492 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 8 / 7 / 4

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 513.01 | Sell |
| EMA (10) | 511.22 | Sell |
| SMA (20) | 507.03 | Buy |
| EMA (20) | 509.27 | Sell |
| SMA (50) | 500.62 | Buy |
| EMA (50) | 499.67 | Buy |
| SMA (100) | 480.36 | Buy |
| EMA (100) | 487.08 | Buy |
| SMA (200) | 473.13 | Buy |
| EMA (200) | 472.58 | Buy |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 50.83 | Neutral |
| MACD (12,26,9) | 3.26 | Sell |
| Stochastic (14,3,3) | 52.54 | Neutral |
| ADX (14) | 14.37 | Neutral |
| Williams %R (14) | -51.91 | Neutral |
| ATR (14) | 15.19 | Neutral |
| ROC (12) | 1.98 | Buy |
| Stoch RSI (14) | 28.44 | Neutral |
| UO (7,14,28) | 51.43 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 5 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |

Based on 5 analyst ratings, observed at 2026-09-11T04:54:15.474378+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-08-29 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=91b87096-9917-41e3-b938-0049855a5ed7.pdf) |
| 2026-08-28 | [Sixteenth Annual General Meeting Of Dr Agarwals Health Care Limited To Be Held On September 21 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=34608850-7936-43cf-a981-b4d964c19856.pdf) |
| 2026-08-28 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27f4b302-a489-4c5f-a079-0af1df1568d1.pdf) |
| 2026-08-27 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b3758d76-a64b-45b5-840a-bf6adc72c04e.pdf) |
| 2026-08-25 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5F7CB3F9_1B31_4DAB_997E_BB8437259168_105656.pdf) |
| 2026-08-25 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8d6c9843-07db-45ba-9322-9a5412718639.pdf) |
| 2026-08-14 | [Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0C6DA864_95AC_49AB_A15B_0D491546D80B_113830.pdf) |
| 2026-08-14 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3A3A6932_D9A4_4855_8F67_EBD6DDE21807_114729.pdf) |
| 2026-08-14 | [Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=CD0A30C0_AB55_47FB_B3C8_59B7D7774D4B_115227.pdf) |
| 2026-08-14 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5BE25CA6_8405_4310_B276_69C5D0C3AA94_115525.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-07 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=949d20e9-ab08-4350-9dcc-1f0c8714b5e4.pdf) |
| 2026-05-27 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=327275b6-f9eb-4265-9f67-077691b429c3.pdf) |
| 2026-02-10 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5fc3b8a3-e72a-40c7-bd2d-4daccec68d27.pdf) |
| 2025-11-04 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3b8075dc-c4b1-42e0-ad21-d09ae92b031a.pdf) |
| 2025-09-03 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b59d4e55-868f-40ab-80cb-d6e2ac656eb7.pdf) |
| 2025-08-16 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cb88f7c8-5f81-4f76-bd69-f9bef4d67530.pdf) |
| 2025-06-02 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7b0acd19-3169-4e63-a16a-0d538867a9fb.pdf) |
| 2025-02-20 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e3a04c60-8326-40ff-b910-64eaf9675210.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-04 | [Consolidated And Standalone Unaudited Financial Results Of The Company For The Quarter Ended June 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=da20ae26-9973-44f7-ab10-e9048e5de932.pdf) |
| 2026-05-21 | [Consolidated And Standalone Audited Financial Results Of The Company For The Quarter And Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dc70db05-f6ac-4568-b257-5bf8934f6433.pdf) |
| 2026-02-03 | [Consolidated And Standalone Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=881c27d6-4afb-4245-b7ee-b33b74c36db4.pdf) |
| 2025-10-30 | [Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0baa1da5-310b-4f33-b320-4f62504eab41.pdf) |
| 2025-08-12 | [Unaudited Financial Results For The Quarter Ended June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bacb9fdf-5fb6-4732-b14d-aed50bb87b56.pdf) |
| 2025-05-28 | [Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=760849ae-f15d-438f-a0a3-9a7d7c14ee3b.pdf) |
| 2025-02-14 | [Results - Quarter And Nine Months Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ad622d3e-63a6-4835-a4a3-8deec8acb24d.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-04 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f986336d-6b97-4989-9603-a81dcc58db45.pdf) |
| 2026-05-21 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f0e08333-46e4-4336-b859-214cace463d9.pdf) |
| 2026-02-03 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9b7fc809-2974-4a46-a3d8-05d02d690444.pdf) |
| 2025-10-31 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5667e58f-facf-4823-b17e-d3765b6459a9.pdf) |
| 2025-08-27 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c950e9b5-0cde-4ade-9808-ffd30a46e803.pdf) |
| 2025-08-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=977ed0a2-c530-426f-b251-99ae29aeabf4.pdf) |
| 2025-05-29 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=561a4399-dcce-4fdb-b6ae-f20a108621f8.pdf) |
| 2025-02-17 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=82fef551-e5e9-4e92-998c-22694b701c27.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-04 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=43c775a6-33f9-4a88-994e-fd8beee94664.pdf) |
| 2026-05-21 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fc6d6b39-cfed-43d4-b875-c9c5c5c4e4f5.pdf) |
| 2026-02-04 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=65272431-bdb7-416d-abba-df78cfcddfcf.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9h - NCLT approved meetings on July 2, 2026 for AEHL-AHCL amalgamation scheme. | [Receipt Of Order Passed By The Hon'Ble NCLT, In Relation To The Scheme Of Amalgamation Between Dr. Agarwal'S Eye Hospital Limited And Dr. Agarwal'S Health Care Limited 9h - NCLT approved meetings on July 2, 2026 for AEHL-AHCL amalgamation scheme.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/7113c702-c031-4697-b21c-5a8bffdb7ab9.pdf) |
| 9 January 2026 - Exchange has sought clarification from Spectrum Talent Management Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. … | [Clarification - Financial Results 9 January 2026 - Exchange has sought clarification from Spectrum Talent Management Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. …](https://www.nseindia.com/companies-listing/corporate-filings-announcements?symbol=SPECTSTM&tabIndex=sme) |
| 8 Apr - Allotment of 1,50,282 Equity Shares pursuant to the exercise of options granted under Dr. Agarwal''s Health Care Limited - Employees Stock Option Scheme 2022 | [Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 8 Apr - Allotment of 1,50,282 Equity Shares pursuant to the exercise of options granted under Dr. Agarwal''s Health Care Limited - Employees Stock Option Scheme 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7bd0756e-bd07-48ee-8714-37604e5106f1.pdf) |
| 7 January 2026 - Certificate under Reg.74(5) for quarter ended 31 Dec 2025: no physical shares received for dematerialization. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 7 January 2026 - Certificate under Reg.74(5) for quarter ended 31 Dec 2025: no physical shares received for dematerialization.](https://nsearchives.nseindia.com/corporate/STML_07012026175146_signed_final_certificate_74_5_.pdf) |
| 6 March 2026 - Board approved STM Global (ADGM) WOS; equity infusion up to USD 10.5M, loan up to USD 1M; explore US acquisition. | [Outcome of Board Meeting 6 March 2026 - Board approved STM Global (ADGM) WOS; equity infusion up to USD 10.5M, loan up to USD 1M; explore US acquisition.](https://nsearchives.nseindia.com/corporate/STML_06032026150103_outcome_of_BM_6_march_2026.pdf) |
| 6 Apr - Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026, is enclosed. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Apr - Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026, is enclosed.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1f282dc7-bd24-4100-9152-f8d947220dfe.pdf) |
| 30 Mar - Idearx ceased as associate effective March 30, 2026; company retains 14.54% equity. | [Update On Announcement Under Regulation 30 (LODR) Dated February 03, 2026 30 Mar - Idearx ceased as associate effective March 30, 2026; company retains 14.54% equity.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c59379d3-17dd-4b00-afb1-e16e0caa85f7.pdf) |
| 21 January 2026 - Approved Abu Dhabi WOS STM Global Ltd (USD10,000) and Indian Section-8 WOS (Rs5 lakh). | [Outcome of Board Meeting 21 January 2026 - Approved Abu Dhabi WOS STM Global Ltd (USD10,000) and Indian Section-8 WOS (Rs5 lakh).](https://nsearchives.nseindia.com/corporate/STML_21012026141708_outcome_of_BM_21_jan_2026.pdf) |
| 18 February 2026 - Promoter Neera Kumar received 194,400 shares (0.84%) via transmission on 17/02/2026, off-market. | [General Updates 18 February 2026 - Promoter Neera Kumar received 194,400 shares (0.84%) via transmission on 17/02/2026, off-market.](https://nsearchives.nseindia.com/corporate/STML_18022026172639_fINAL_FORM_c.pdf) |
| 14 November 2025 - No deviation in utilisation of Rs.6.18 crore preferential issue proceeds for half-year ended 30 Sep 2025. | [Statement of deviation(s) or variation(s) under Reg. 32 14 November 2025 - No deviation in utilisation of Rs.6.18 crore preferential issue proceeds for half-year ended 30 Sep 2025.](https://nsearchives.nseindia.com/corporate/STML_14112025184916_statement_of_deviation.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2025 | [Concall - Sep 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b59d4e55-868f-40ab-80cb-d6e2ac656eb7.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3b8075dc-c4b1-42e0-ad21-d09ae92b031a.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://nsearchives.nseindia.com/corporate/SPECTSTM_25112024094121_Transcriptofconall.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://nsearchives.nseindia.com/corporate/SPECTSTM_29112023160022_Transcript.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/327275b6-f9eb-4265-9f67-077691b429c3.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/327275b6-f9eb-4265-9f67-077691b429c3.pdf) |
| May 2024 | [Concall - May 2024](https://nsearchives.nseindia.com/corporate/SPECTSTM_31052024174443_Transcriptofconcall28thmay2024.pdf) |
| Jun 2025 | [Concall - Jun 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7b0acd19-3169-4e63-a16a-0d538867a9fb.pdf) |
| Jun 2025 | [Concall - Jun 2025](https://nsearchives.nseindia.com/corporate/STML_04062025181230_Investor_presentation_march_2025.pdf) |
| Jul 2023 | [Concall - Jul 2023](https://archives.nseindia.com/corporate/SPECTSTM_04072023172616_Investerpresention.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_27714_SPECTSTM_2024_2025_A_4404263_26082025173449.pdf) |
| from nse | [Financial Year 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_25368_SPECTSTM_2023_2024_3108202414294.pdf) |
| from nse | [Financial Year 2023 from nse](https://archives.nseindia.com/annual_reports/SME_AR_22942_SPECTSTM_2022_2023_25082023173823_08252023180013.zip) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/dca23e4c-b2c0-448b-9caa-30e6e3456b77.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:50:24.938Z.